Shots:
- The EC has approved Tryngolza (olezarsen) as an adjunct to diet in adult patients for the treatment of genetically confirmed familial chylomicronemia syndrome
- Approval was based on P-III (Balance) trial assessing Tryngolza (Q4W) vs PBO, which showed reduced triglyceride levels at 6mos., sustained through 12mos., with decrease in acute pancreatitis events over 12mos.; data was published in The NEJM
- Tryngolza is also being studied in a P-III trial among pts with sHTG & triglyceride levels ≥500 mg/dL, with data expected to be released by Sep 2025
Ref: Sobi| Image: Ionis | Press Release
Related News:- Ionis’ ION582 Receives the US FDA’s Breakthrough Therapy Designation to Treat Angelman Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
